The US Food and Drug Administration (FDA) has cleared Angioslide's new Proteus device for treating peripheral artery disease in below the knee (BTK) vasculature.

The new 3X100mm device includes 0.014 guide-wires and its proprietary technology combines the functionality of a balloon angioplasty device with the addition of built-in embolic capture.

Proteus is a percutaneous transluminal angioplasty balloon, which during deflation captures and removes harmful embolic material from the body.

Angioslide CEO Lihu Avitov said introduction of the new BTK, low-profile Proteus platform, supports the company’s commitment to improve procedure outcomes.

"PROTEUS will become a necessary device in the "tool-box" of physicians practicing "endovascular-first" approach," Avitov added.